• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑癌基因 ADAM12 在慢性淋巴细胞白血病患者中的异常甲基化:甲基化特异性 PCR 技术的应用。

Aberrant Methylation of Tumour Suppressor Gene ADAM12 in Chronic Lympocytic Leukemia Patients: Application of Methylation Specific-PCR Technique.

机构信息

Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia.

Department of Hematology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia.

出版信息

Asian Pac J Cancer Prev. 2021 Jan 1;22(1):85-91. doi: 10.31557/APJCP.2021.22.1.85.

DOI:10.31557/APJCP.2021.22.1.85
PMID:33507683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8184192/
Abstract

OBJECTIVE

Chronic Lymphocytic Leukemia (CLL) is a common leukemia among Caucasians but rare in Asians population. We postulated that aberrant methylation either hypermethylation or partial methylation might be one of the silencing mechanisms that inactivates the tumour suppressor genes in CLL. This study aimed to compare the methylation status of tumour suppressor gene, ADAM12, among CLL patients and normal individuals. We also evaluated the association between methylation of ADAM12 and clinical and demographic characteristics of the participants.

METHODS

A total of 25 CLL patients and 25 normal individuals were recruited in this study. The methylation status of ADAM12 was determined using Methylation-Specific PCR (MSP); whereas, DNA sequencing method was applied for validation of the MSP results.

RESULTS

Among CLL patients, 12 (48%) were partially methylated and 13 (52%) were unmethylated. Meanwhile, 5 (20%) and 20 (80.6%) of healthy individuals were partially methylated and unmethylated, respectively. There was a statistically significant association between the status of methylation at ADAM12 and the presence of CLL (p=0.037).

CONCLUSION

The aberrant methylation of ADAM12 found in this study using MSP assay may provide new exposure to CLL that may improve the gaps involved in genetic epigenetic study in CLL.

摘要

目的

慢性淋巴细胞白血病(CLL)在白种人群中较为常见,但在亚洲人群中较为罕见。我们推测,异常甲基化(包括过度甲基化或部分甲基化)可能是沉默 CLL 中肿瘤抑制基因的机制之一。本研究旨在比较 CLL 患者和正常个体中肿瘤抑制基因 ADAM12 的甲基化状态。我们还评估了 ADAM12 甲基化与参与者临床和人口统计学特征之间的关联。

方法

本研究共纳入 25 例 CLL 患者和 25 例正常个体。采用甲基化特异性 PCR(MSP)检测 ADAM12 的甲基化状态;同时,应用 DNA 测序法验证 MSP 结果。

结果

在 CLL 患者中,有 12 例(48%)呈部分甲基化,13 例(52%)呈非甲基化。而在健康个体中,有 5 例(20%)和 20 例(80.6%)分别呈部分甲基化和非甲基化。ADAM12 甲基化状态与 CLL 的存在之间存在统计学显著关联(p=0.037)。

结论

本研究采用 MSP 检测到 ADAM12 的异常甲基化,可能为 CLL 提供新的认识,有助于填补 CLL 中遗传表观遗传学研究的空白。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5802/8184192/0da33f0b10fa/APJCP-22-085-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5802/8184192/1c4eb423bffa/APJCP-22-085-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5802/8184192/52e4d514742f/APJCP-22-085-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5802/8184192/0da33f0b10fa/APJCP-22-085-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5802/8184192/1c4eb423bffa/APJCP-22-085-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5802/8184192/52e4d514742f/APJCP-22-085-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5802/8184192/0da33f0b10fa/APJCP-22-085-g003.jpg

相似文献

1
Aberrant Methylation of Tumour Suppressor Gene ADAM12 in Chronic Lympocytic Leukemia Patients: Application of Methylation Specific-PCR Technique.抑癌基因 ADAM12 在慢性淋巴细胞白血病患者中的异常甲基化:甲基化特异性 PCR 技术的应用。
Asian Pac J Cancer Prev. 2021 Jan 1;22(1):85-91. doi: 10.31557/APJCP.2021.22.1.85.
2
Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia.慢性淋巴细胞白血病中肿瘤抑制性长链非编码RNA BM742401的表观遗传沉默
Oncotarget. 2016 Dec 13;7(50):82400-82410. doi: 10.18632/oncotarget.12252.
3
Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFκB pathway.慢性淋巴细胞白血病中 miR-9 家族 microRNAs 的表观遗传失活--对 NFκB 通路持续激活的影响。
Mol Cancer. 2013 Dec 27;12:173. doi: 10.1186/1476-4598-12-173.
4
Large-scale analysis of DNA methylation in chronic lymphocytic leukemia.大规模分析慢性淋巴细胞白血病中的 DNA 甲基化。
Epigenomics. 2009 Oct;1(1):39-61. doi: 10.2217/epi.09.10.
5
Assessment of Promoter Methylation Identifies PTCH as a Putative Tumor-suppressor Gene in Human CLL.启动子甲基化评估确定PTCH为人类慢性淋巴细胞白血病中的一个假定肿瘤抑制基因。
Anticancer Res. 2016 Sep;36(9):4515-9. doi: 10.21873/anticanres.10998.
6
Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia.慢性淋巴细胞白血病中除了 mir-34a 和 DAPK1 之外,mir-34b/c 的表观遗传失活。
J Transl Med. 2014 Feb 22;12:52. doi: 10.1186/1479-5876-12-52.
7
Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact.对慢性淋巴细胞白血病进行全基因组 DNA 甲基化分析,可鉴定出具有临床影响的表观遗传抑制分子途径。
Epigenetics. 2010 Aug 16;5(6):499-508. doi: 10.4161/epi.5.6.12179.
8
Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia.慢性淋巴细胞白血病预后亚组中基于全基因组芯片的差异甲基化图谱。
Blood. 2010 Jan 14;115(2):296-305. doi: 10.1182/blood-2009-07-232868. Epub 2009 Nov 6.
9
Epigenetic profile in chronic lymphocytic leukemia using methylation-specific multiplex ligation-dependent probe amplification.采用甲基化特异性多重连接依赖性探针扩增技术分析慢性淋巴细胞白血病的表观遗传学特征。
Epigenomics. 2012 Oct;4(5):491-501. doi: 10.2217/epi.12.40.
10
Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.慢性淋巴细胞白血病中蛋白酪氨酸磷酸酶O型受体的甲基化与沉默
Clin Cancer Res. 2007 Jun 1;13(11):3174-81. doi: 10.1158/1078-0432.CCR-06-1720.

引用本文的文献

1
The Role of Methylation in Chronic Lymphocytic Leukemia and Its Prognostic and Therapeutic Impacts in the Disease: A Systematic Review.甲基化在慢性淋巴细胞白血病中的作用及其对该疾病的预后和治疗影响:一项系统综述
Adv Hematol. 2024 Feb 23;2024:1370364. doi: 10.1155/2024/1370364. eCollection 2024.

本文引用的文献

1
Comparison of the anti-cancer effect of Disulfiram and 5-Aza-CdR on pancreatic cancer cell line PANC-1.双硫仑与5-氮杂-2'-脱氧胞苷对胰腺癌细胞系PANC-1抗癌作用的比较。
Adv Biomed Res. 2014 Jul 31;3:156. doi: 10.4103/2277-9175.137866. eCollection 2014.
2
The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?ADAMs 蛋白酶家族:癌症的新型生物标志物和治疗靶点?
Clin Proteomics. 2011 Jun 9;8(1):9. doi: 10.1186/1559-0275-8-9.
3
Molecular profiling of ADAM12 gene in breast cancers.乳腺癌中ADAM12基因的分子特征分析。
Rom J Morphol Embryol. 2010;51(4):669-76.
4
Large-scale analysis of DNA methylation in chronic lymphocytic leukemia.大规模分析慢性淋巴细胞白血病中的 DNA 甲基化。
Epigenomics. 2009 Oct;1(1):39-61. doi: 10.2217/epi.09.10.
5
Targeting ADAM12 in human disease: head, body or tail?针对人类疾病中的ADAM12:头部、主体还是尾部?
Curr Pharm Des. 2009;15(20):2300-10. doi: 10.2174/138161209788682389.
6
Role of ADAMs in cancer formation and progression.ADAMs在癌症形成和进展中的作用。
Clin Cancer Res. 2009 Feb 15;15(4):1140-4. doi: 10.1158/1078-0432.CCR-08-1585.
7
The ADAMs: signalling scissors in the tumour microenvironment.ADAMs:肿瘤微环境中的信号剪刀
Nat Rev Cancer. 2008 Dec;8(12):929-41. doi: 10.1038/nrc2459. Epub 2008 Nov 13.
8
Heparan sulfate regulates ADAM12 through a molecular switch mechanism.硫酸乙酰肝素通过分子开关机制调节解聚素金属蛋白酶12。
J Biol Chem. 2008 Nov 14;283(46):31920-32. doi: 10.1074/jbc.M804113200. Epub 2008 Sep 17.
9
The ADAM metalloproteinases.ADAM金属蛋白酶
Mol Aspects Med. 2008 Oct;29(5):258-89. doi: 10.1016/j.mam.2008.08.001. Epub 2008 Aug 15.
10
Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment.尿金属蛋白酶:用于乳腺癌风险评估的非侵入性生物标志物。
Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1034-42. doi: 10.1158/1055-9965.EPI-07-0365.